The US Food and Drug Administration has approved a second new drug in two weeks to treat chronic hepatitis C virus infection – Sovaldi (sofosbuvir) from Gilead Sciences Inc. Sovaldi is the first drug for certain HCV genotypes that won’t need co-treatment with interferon.
